THERAPEUTIC INNOVATION IN PANCREATIC CANCER: CLINICAL, ECONOMIC, AND HEALTHCARE IMPLICATIONS OF THE INTRODUCTION OF DARAXONRASIB INTO ONCOLOGY PRACTICE

Abstract

Pancreatic cancer remains one of the malignancies with the poorest prognosis, characterized by high mortality rates and limited therapeutic options, particularly in advanced stages. In this context, this chapter aims to analyze the clinical, economic, and healthcare implications of introducing daraxonrasib into contemporary oncology practice. The methodology consisted of a narrative review of national and international scientific literature, including indexed articles, clinical studies, and technical documents published between 2020 and 2026, focusing on targeted therapies directed at KRAS gene mutations. The findings indicate that daraxonrasib represents an innovative therapeutic strategy by specifically targeting molecular alterations associated with tumor progression, contributing to improved survival outcomes, better disease control, and potentially fewer adverse effects when compared with conventional treatments. However, its incorporation into healthcare systems presents challenges related to high costs, the need for genomic testing, and the reorganization of specialized services to ensure equitable access for eligible patients. It is concluded that daraxonrasib has the potential to transform pancreatic cancer management, highlighting the importance of precision medicine and the continuous assessment of its clinical, economic, and healthcare impacts in modern oncology.